4.8 Article

Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1603269113

关键词

innate immunity; signaling; type I interferon; transcription factor; crystal structure

资金

  1. National Institutes of Health [AI 087741]
  2. Welch Foundation [A-1816]
  3. Cancer Prevention and Research Institute of Texas [RP150454]
  4. National Institute of General Medical Sciences
  5. Howard Hughes Medical Institute
  6. Office of Science, Office of Basic Energy Sciences, of the US Department of Energy [DE-AC02-05CH11231]

向作者/读者索取更多资源

Type I IFNs are key cytokines mediating innate antiviral immunity. cGMP-AMP synthase, ritinoic acid-inducible protein 1 (RIG-I)-like receptors, and Toll-like receptors recognize microbial double-stranded (ds) DNA, dsRNA, and LPS to induce the expression of type I IFNs. These signaling pathways converge at the recruitment and activation of the transcription factor IRF-3 (IFN regulatory factor 3). The adaptor proteins STING (stimulator of IFN genes), MAVS (mitochondrial antiviral signaling), and TRIF (TIR domain-containing adaptor inducing IFN-beta) mediate the recruitment of IRF-3 through a conserved pLxIS motif. Here we show that the pLxIS motif of phosphorylated STING, MAVS, and TRIF binds to IRF-3 in a similar manner, whereas residues upstream of the motif confer specificity. The structure of the IRF-3 phosphomimetic mutant S386/396E bound to the cAMP response element binding protein (CREB)-binding protein reveals that the pLxIS motif also mediates IRF-3 dimerization and activation. Moreover, rotavirus NSP1 (nonstructural protein 1) employs a pLxIS motif to target IRF-3 for degradation, but phosphorylation of NSP1 is not required for its activity. These results suggest a concerted mechanism for the recruitment and activation of IRF-3 that can be subverted by viral proteins to evade innate immune responses.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据